<DOC>
	<DOCNO>NCT00614055</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare two NN5401 ( SIAC , insulin degludec/insulin aspart ) formulation insulin glargine , combination metformin insulin naive subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Two NN5401 Formulations Versus Insulin Glargine , All Combination With Metformin Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject . ) Insulin na√Øve type 2 diabetes subject ( diagnose clinically ) least 3 month ( previous insulin treatment previous short term insulin treatment maximum 14 day within last 3 month ) Treatment one two oral antidiabetic drug ( OADs ) : metformin , sulfonylurea , insulin secretagogue ( e.g . repaglinide , nateglinide ) , alphaglucosidase inhibitor least 2 month stable maximum tolerate dose least half maximum allow dose accord locally approve summary product characteristic ( SPC ) HbA1c , 7.0 11.0 % ( inclusive ) Body Mass Index ( BMI ) , 25.0 37.0 kg/m^2 ( inclusive ) Metformin contraindication accord local practice Thiazolidinedione ( TZD ) treatment within previous three month prior Visit 1 Any systemic treatment product , investigator 's opinion could interfere glucose lipid metabolism ( e.g . systemic corticosteroid ) within 3 month prior randomisation Subject clinically significant , active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , genitourinary , haematological system , opinion investigator , may confound result trial pose additional risk administer trial product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>